GlassScriptPhysician profile
Mary M Spolyar
NPI 1932169349
$17,117.60
in general payments reported to CMS, 2019-2025
35 companies · $3,573 in 2025
The $3,573 reported for 2025 was more than what 86% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,364 · 2020: $1,217 · 2021: $1,770 · 2022: $2,418 · 2023: $2,399 · 2024: $4,377 · 2025: $3,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,135 · Consulting Fee: $1,875 · Education: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,134.94 |
| Consulting Fee | $1,875.00 |
| Education | $339.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,483.65 | 2019-2025 | Rinvoq, Skyrizi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,182.28 | 2023-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $1,785.19 | 2019-2025 | |
| Pfizer INC. | $1,408.69 | 2019-2025 | |
| Incyte Corporation | $1,331.76 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,271.36 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,212.74 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $844.15 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $821.58 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $774.87 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $663.29 | 2019-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $484.31 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $345.78 | 2019-2025 | Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $328.62 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $138.80 | 2022-2025 | Sotyktu |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $133.59 | 2020-2025 | Adbry, Spevigo |
| Genzyme Corporation | $127.37 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $120.86 | 2021 | |
| Stemline Therapeutics INC. | $112.48 | 2022 | |
| Celgene Corporation | $90.04 | 2019 | |
| Mayne Pharma Commercial LLC | $69.30 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.77 | 2019-2020 | |
| Organon LLC | $59.56 | 2024-2025 | Vtama |
| Dermira, INC. | $45.56 | 2020 | |
| Vyne Pharmaceuticals INC. | $40.67 | 2021 | |
| Almirall LLC | $35.34 | 2019 | |
| Aclaris Therapeutics, INC. | $29.14 | 2019 | |
| Verrica Pharmaceuticals INC. | $19.42 | 2025 | Ycanth |
| Mylan Institutional INC. | $16.04 | 2023 | Hulio |
| Botanix Sb INC | $15.88 | 2025 | Sofdra |
| Journey Medical Corporation | $15.10 | 2023 | |
| Merck Sharp & Dohme LLC | $14.93 | 2019 | |
| Biofrontera INC. | $13.38 | 2019 | |
| Epi Health, LLC | $11.67 | 2021 | |
| Prugen, INC. Pharmaceuticals | $9.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Spolyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.